National Center for Infection Control, Ministry of Health, Tel-Aviv, Israel.
J Clin Microbiol. 2013 Sep;51(9):2926-30. doi: 10.1128/JCM.01049-13. Epub 2013 Jun 26.
This study describes the course of an OXA-48-producing Enterobacteriaceae (OPE) outbreak that started in March 2012 in a neonatal intensive care unit (NICU) in Jerusalem, Israel. During the peak of the outbreak (January to August 2012), there were 49 patients who had proven or suspected acquisition of OPE in the NICU, including 16 with invasive infections, out of a total of 156 patients who were hospitalized during that period. Three children hospitalized in the pediatric ICU were identified as carriers of OPE. Three patients with a previous stay in the affected NICU were identified as OPE carriers upon admission to another hospital. The Ministry of Health was notified and then intervened in July 2012. Intervention included cohorting colonized patients, conducting frequent rectal-culture surveillance, and improving the implementation of infection control practices. As a result, the incidence of OPE acquisition declined to 5 cases in the first 4 months, followed by no new cases in the next 3 months. Thirty-one patient-unique isolates were available for analysis: 29 Klebsiella pneumoniae isolates, all belonging to a single clone (sequence type 39 [ST39]), and 2 isolates from Enterobacter cloacae. All isolates possessed the blaOXA-48 and blaCTX-M-14 genes, which are located on the same plasmid. This plasmid, similar to the global blaOXA-48-harboring vector, has now acquired blaCTX-M-14, leading to resistance to all β-lactam agents.
本研究描述了 2012 年 3 月在以色列耶路撒冷一家新生儿重症监护病房(NICU)开始的产 OXA-48 型肠杆菌科细菌(OPE)爆发的过程。在爆发高峰期(2012 年 1 月至 8 月),共有 49 名在 NICU 中确诊或疑似获得 OPE 的患者,其中 16 名患有侵袭性感染,而同期住院患者总数为 156 名。3 名在儿科重症监护病房住院的儿童被确定为 OPE 携带者。另有 3 名曾在受影响的 NICU 住院的患者在另一家医院住院时被确定为 OPE 携带者。卫生部接到通知后于 2012 年 7 月进行了干预。干预措施包括对定植患者进行分组、频繁进行直肠培养监测,并改进感染控制措施的实施。结果,OPE 获得的发病率在头 4 个月下降到 5 例,随后的 3 个月内没有新发病例。共有 31 株患者独特的分离株可供分析:29 株肺炎克雷伯菌分离株,均属于单一克隆(序列类型 39 [ST39]),2 株来自阴沟肠杆菌。所有分离株均携带 blaOXA-48 和 blaCTX-M-14 基因,这些基因位于同一质粒上。该质粒与全球 blaOXA-48 携带载体相似,现已获得 blaCTX-M-14,导致对所有β-内酰胺类药物产生耐药性。